Baricitinib in combo with Remdesivir reduces time to recovery in COVID-19 hospitalized pts in NIH-run ACTT-2 Trial w/ >1000 pts randomized to recv 4-mg baricitinib plus remdesivir versus remdesivir alone. Other baricitinib-COVID trials are in progress https://t.co/J87Ypeb4mn

Proof-of-concept study colchicine use in the context of COVID-19 infection leads to better survival. 140 consecutive COVID inpatients were Rx w/ standard of care +/- Colchicine. Survival rate @21d was better w/ colchicine (84% vs 64%;p=0.001). https://t.co/OzYd7pZ2ys

Danish matched (1:4) cohort study shows COVID-19 pts taking NSAIDs had no greater risk of mortality, hospitalization, ICU admission, mechanical ventilation, or renal replacement therapy; study included 9,236 COVID PCR-positive & 2.7% were on NSAIDs https://t.co/OuUbJ9FxiM

Cell phone use and location data during the COVID pandemic shows greater reductions in cell phone activity in the workplace and retail locations, and greater increases in activity at the residence, are associated with lesser growth in COVID-19 cases. https://t.co/3tRAbqqy4i

Another metanalysis of Chloroquine, HCQ, or azithromycin in COVID-19 shows HCQ not associated w/ reduced mortality (RR=0.83; 0.65-1.06) in hospitalized COVID-19, but combo of HCQ & azithromycin significantly increased mortality (RR=1.27; 1.04-1.54) https://t.co/xGEGyywxBJ

Sanofi suspended Kevzara (sarilumab; 200 or 400 mg) studies in severe hospitalized COVID-19 infx - phase 3 trials didnt meet primary or secondary endpoints vs PBO. 420-Pt multinational trial had similar SAE and death rates in all 3 arms https://t.co/YkuKnVm9B8

President Trump took HCQ/Azithromycin.... Lancet Rheumatology reports that HCQ in RA has no cardiac risk but long term HCQ increases risk cardiovascular mortality, that may be further augmented by azithromycin. https://t.co/JRtkkAuEeu

RheumNow Podcast is Up! Rheum Lives Matter. More about social change, HCQ, JAKs & skin, growing cartilage, FM exercise. Watch it here>https://t.co/LLvADsDJ5O or listen to the Podcast here>https://t.co/pCXzaJUS9s

To date, the FDA has currently authorized 218 tests under EUAs; these include 176 molecular tests, 39 antibody tests, and 3 antigen tests.